I am pleased to read many new research articles on the use of antiviral antiseptics against COVID-19. I hope to see many more in 2021. Antivirals may help people who are yet unable or unwilling to obtain the vaccine. In the meantime, I suggest my professional colleagues read these journal articles with the scientific method in mind. Our personal beliefs or assumptions may be discussed but should not be presented as, nor confused with, scientific conclusions. Furthermore, in the U.S. it is the FDA & CDC that make the final decisions regarding the safety & efficacy of any COVID-19 drug. Seek guidance from the ADA & the AMA regarding specific manufacturer’s claims.
Separately, it appears that the COVID-19 pandemic is increasing the disruption of private practice towards corporate dentistry chains that are frequently owned by private equity firms. Additionally, dentists are restricted from simple movement between treatment rooms due to new requirements for changing all PPE. And it is illegal to charge to cover the increased cost of PPE. Therefore, one may expect a decrease in conservative, lower-cost procedures unless these laws are changed.
Dr. Dorfman is a paid consultant to Avrio Health, a subsidiary of Purdue Pharma L.P. The opinion expressed here is his own.
Categorised in: Dr. Dorfman Says
This post was written by Dr. Jeffrey Dorfman